GlaxoSmithKline

A picture of the UNC and GSK press conference.
WUNC

UNC-Chapel Hill announced a partnership this week with pharmaceutical giant GlaxoSmithKline to work on a cure for AIDS.

Scientists say what once was a lofty goal is now more realistic, thanks in part to UNC's already-extensive AIDS research. 

GSK and UNC will create a company called Qura Therapeutics to oversee more research at UNC laboratories, with an eye on producing a cure within the next 30 years.

Host Frank Stasio talks with Triangle Business Journal reporter Jason deBruyn about the details of the partnership.

A picture of the UNC and GSK press conference.
WUNC

UNC-Chapel Hill has teamed up with pharmaceutical giant GlaxoSmithKline to find a cure for HIV/AIDS.

Chancellor Carol Folt announced the creation of Qura Therapeutics, which will oversee the new HIV Cure center. The center will bring together researchers from UNC and GSK.

GSK will contribute $20 million for the first five years.

GSK CEO Andrew Witty says research on the virus has come a long way since the 1980s, when a cure for AIDS was thought to be impossible.

GlaxoSmithKline
GlaxoSmithKline

    

Pharmaceutical giant GlaxoSmithKline eliminated 900 jobs yesterday.

Image of GlaxoSmithKline headquarters in west London.
Flickr/Ian Wilson

    

Pharmaceutical player GlaxoSmithKline is laying off hundreds of workers in its American facilities, and the bulk of these job cuts are in Research Triangle Park.

A picture of a stethoscope.
jasleen_kaur / Flickr/Creative Commons

Health care organizations in North Carolina are expanding an initiative to see how doctors and pharmacists cooperate to streamline patient care.

Community Care of North Carolina has already set up a program in which 3,000 GlaxoSmithKline employees see doctors who coordinate all their treatment.

But CCNC President Doctor Allen Dobson says that primary care physicians don't always know all the medications a patient is taking, especially if they're seeing other specialists for multiple conditions.

GlaxoSmithKline
www.gsk.com

Big changes and asset swaps in the pharmaceutical world are happening this week, but the Triangle should be spared of any fall-out.

One of the big moves in this chess game includes Switzerland-based Novartis agreeing to spend up to $16 billion for GlaxoSmithKline’s cancer drug business in Pennsylvania.

RTP headquarters.
Ildar Sagdejev

GlaxoSmithKline hosted a gathering today in RTP for policy, non-profit and business leaders in the biopharmaceutical industry.

Jack Bailey, a Senior Vice President at GSK, says there are well over 100,000 North Carolinians working in the Life Sciences, 5,000 of them at his company.

“So it’s a very big important industry, it’s created a lot of jobs," Bailey says. "And really what we want to do today is start a discussion on how, at this great change in health care, we can make sure both federal, state and local policy decisions get made that continue to accelerate that innovation that comes out of companies like GSK.”

GlaxoSmithKline
GlaxoSmithKline

Authorities in China say a number of senior executives working for GlaxoSmithKline in that country have been placed under criminal investigation for suspected bribery and tax related violations.  The British pharmaceutical company's US headquarters are in Research Triangle Park. 

In an interview broadcast on WUNC, the BBC’s John Sudworth reported that the ministry of public security said the employees offered large bribes to officials, medical associations, hospitals and doctors to boost drug sales.

More bad news for Glaxo Smith Kline as the company attempts to account for the costs of Avandia litigation. .

GSK made the announcement in a statement posted on the company's website. Glaxo will take a $3.4 billion write-off out of fourth quarter profits to cover liability costs for blockbuster diabetes drug Avandia.